Policy | August 06, 2021
Govt augments PSEs and Bharat Biotech to ramp up Covaxin production
CDSCO to fast-track trials and approval for COVID19 vaccine
CDSCO to fast-track trials and approval for COVID19 vaccine
It is part of the company’s pain/analgesics portfolio of OTC products
Five seats reserved for Wards of COVID warriors in central MBBS admission
It is designed to tackle mental health issues
Robust demand for the product across the Middle East, Africa and Latin America
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
Complementary business models are the reason for the acquisition
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Subscribe To Our Newsletter & Stay Updated
